Abstract
In a randomised phase 3 trial, panitumumab significantly improved progression-free survival (PFS) in patients with refractory metastatic colorectal cancer (mCRC). This analysis characterises the association of PFS with CRC symptoms, health-related quality of life (HRQoL), and overall survival (OS). CRC symptoms (NCCN/FACT CRC symptom index, FCSI) and HRQoL (EQ-5D) were assessed for 207 panitumumab patients and 184 best supportive care (BSC) patients who had at least one post-baseline patient-reported outcome (PRO) assessment. Patients alive at week 8 were included in the PRO and OS analyses and categorised by their week 8 progression status as follows: no progressive disease (no PD; best response of at least stable disease) vs progressive disease (PD). Standard imputation methods were used to assign missing values. Significantly more patients were progression free at weeks 8-24 with panitumumab vs BSC. After excluding responders, a significant difference in PFS remained favouring panitumumab (HR=0.63, 95% CI=0.52-0.77; P
Original language | English |
---|---|
Pages (from-to) | 1469-1474 |
Number of pages | 6 |
Journal | British Journal of Cancer |
Volume | 97 |
Issue number | 11 |
DOIs | |
Publication status | Published - Dec 3 2007 |
Keywords
- Disease progression
- Improvement
- Panitumumab
- Patient-reported outcomes
- Quality of life
- Symptom
ASJC Scopus subject areas
- Cancer Research
- Oncology